Brief: Tracon Pharmaceuticals Announces Results Of Second Independent Data Monitoring Committee Review Of Safety Data From Envasarc Pivotal Trial

TRACON Pharmaceuticals

09/08/2021 15:11

Aug 9 (Reuters) - TRACON Pharmaceuticals Inc  TCON.O :
    * TRACON PHARMACEUTICALS ANNOUNCES RESULTS OF SECOND
INDEPENDENT
DATA MONITORING COMMITTEE REVIEW OF SAFETY DATA FROM ENVASARC
PIVOTAL TRIAL
    * TRACON PHARMACEUTICALS INC - INDEPENDENT DATA MONITORING
COMMITTEE FOR ENVASARC PIVOTAL TRIAL HAS RECOMMENDED THAT TRIAL
PROCEED AS PLANNED
    * TRACON PHARMACEUTICALS - ENVAFOLIMAB CONTINUES TO BE WELL
TOLERATED AS A SINGLE AGENT AND WHEN COMBINED WITH YERVOY IN
ENROLLED PATIENTS
    * TRACON PHARMACEUTICALS INC - REMAIN ON TRACK FOR
INDEPENDENT
DATA MONITORING COMMITTEE TO REVIEW INTERIM EFFICACY DATA IN Q4
OF 2021

Source text for Eikon:  ID:nGNX5qlh3m 
Further company coverage:  TCON.O 

 ((reuters.briefs@thomsonreuters.com;))